Alcon Beheer

Beheer criteriumcontroles 4/4

De CEO Alcon is David Endicott, benoemd in Jul2018, heeft een ambtstermijn van 6.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 12.33M, bestaande uit 10.7% salaris en 89.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.047% van de aandelen van het bedrijf, ter waarde $ 21.46M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5 jaar en 5.8 jaar.

Belangrijke informatie

David Endicott

Algemeen directeur

US$12.3m

Totale compensatie

Percentage CEO-salaris	10.7%
Dienstverband CEO	6.3yrs
Eigendom CEO	0.05%
Management gemiddelde ambtstermijn	5yrs
Gemiddelde ambtstermijn bestuur	5.8yrs

Recente managementupdates

Recent updates

Alcon to acquire U.S. commercialization rights to ophthalmic eye drops Simbrinza from Novartis

Apr 28

Alcon: Global Leader In An Attractive End-Market

Dec 16

Alcon Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 11

Alcon Q3 2020 Earnings Preview

Nov 09

Analyse CEO-vergoeding

Hoe is David Endicott's beloning veranderd ten opzichte van Alcon's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	US$1b
Mar 31 2024	n/a	n/a	US$1b
Dec 31 2023	US$12m	US$1m	US$974m
Sep 30 2023	n/a	n/a	US$450m
Jun 30 2023	n/a	n/a	US$362m
Mar 31 2023	n/a	n/a	US$341m
Dec 31 2022	US$10m	US$1m	US$335m
Sep 30 2022	n/a	n/a	US$571m
Jun 30 2022	n/a	n/a	US$457m
Mar 31 2022	n/a	n/a	US$460m
Dec 31 2021	US$11m	US$1m	US$376m
Sep 30 2021	n/a	n/a	US$332m
Jun 30 2021	n/a	n/a	US$183m
Mar 31 2021	n/a	n/a	-US$390m
Dec 31 2020	US$8m	US$1m	-US$531m
Sep 30 2020	n/a	n/a	-US$717m
Jun 30 2020	n/a	n/a	-US$636m
Mar 31 2020	n/a	n/a	-US$604m
Dec 31 2019	US$7m	US$1m	-US$656m

Compensatie versus markt: De totale vergoeding ($USD 12.33M ) David } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.91M ).

Compensatie versus inkomsten: De vergoeding van David is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

David Endicott (59 yo)

6.3yrs

Tenure

US$12,325,391

Compensatie

Mr. David J. Endicott is President and Chief Executive Officer at Aerie Pharmaceuticals, Inc. since November 21, 2022. He had been the Chief Executive Officer of Alcon, Inc. since July 1, 2018. He is the C...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
F. Ball	Executive Chairman	5.8yrs	US$1.17m	0.011% $ 5.2m
David Endicott	CEO & Director	6.3yrs	US$12.33m	0.047% $ 21.5m
Arthur Cummings	Executive Director	no data	US$284.68k	0.0012% $ 533.0k
Timothy Stonesifer	Chief Financial Officer	5.6yrs	geen gegevens	0.020% $ 8.9m
Ian Bell	Senior VP & COO	less than a year	geen gegevens	0.0081% $ 3.7m
Margaret Buckley	Chief Accounting Officer	no data	geen gegevens	geen gegevens
Franck Leveiller	Senior VP	2.4yrs	geen gegevens	geen gegevens
Royce Bedward	Senior VP	no data	geen gegevens	geen gegevens
Kimberly Martin	Senior VP	4.3yrs	geen gegevens	geen gegevens
Laurent Attias	Head of Corporate Development	no data	geen gegevens	0.0040% $ 1.8m
Leon Sergio Fraustro	President of North America	9.3yrs	geen gegevens	0.0043% $ 1.9m
Ed McGough	Senior VP and Head of Global Manufacturing & Technical Operations	no data	US$2.03m	geen gegevens

5.0yrs

Gemiddelde duur

57.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ALC wordt beschouwd als ervaren (gemiddelde ambtstermijn 5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
F. Ball	Executive Chairman	5.8yrs	US$1.17m	0.011% $ 5.2m
David Endicott	CEO & Director	5.8yrs	US$12.33m	0.047% $ 21.5m
Arthur Cummings	Executive Director	5.8yrs	US$284.68k	0.0012% $ 533.0k
Karen May	Independent Director	5.8yrs	US$325.52k	0.0052% $ 2.3m
D. Grossman	Independent Vice Chair	5.8yrs	US$361.69k	0.0031% $ 1.4m
Thomas Glanzmann	Independent Director	5.8yrs	US$352.98k	0.0041% $ 1.9m
Dieter Spälti	Independent Director	5.8yrs	US$236.83k	0.0049% $ 2.2m
Scott Maw	Independent Director	5.8yrs	US$333.87k	0.0031% $ 1.4m
Lynn Bleil	Independent Director	5.8yrs	US$296.31k	0.0019% $ 888.3k
Ines Pöschel	Independent Director	5.8yrs	US$293.86k	0.0021% $ 965.7k
RaQuel Bono	Independent Director	2.6yrs	US$256.66k	0.00057% $ 259.7k

5.8yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ALC wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.8 jaar).

Alcon Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Alcon Announces Management Changes

Alcon Inc., Annual General Meeting, May 08, 2024

Alcon Inc., Annual General Meeting, May 05, 2023

Insufficient new directors

Insufficient new directors

Alcon Inc., Annual General Meeting, Apr 28, 2021

Recent updates

Alcon Q2: Positive News From Unity VCS/CS And AR-15512

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Alcon Inc. Maintains Earnings Guidance for the Year 2024

Now 21% undervalued

Alcon: Trading At An Undeserved Premium Valuation

Alcon's Latest Equipment Breakthrough Technologies, Unity VCS and Unity CS, Receive U.S. FDA 510(k) Clearance

First quarter 2024 earnings: EPS exceeds analyst expectations

Alcon Q1: Robust Product Pipeline Drives Future Growth (Rating Upgrade)

Upcoming dividend of CHF0.16 per share

Alcon Inc. Approves Gross Dividend

Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and Its Hydrus Microstent for Microinvasive Glaucoma Surgery

Alcon Announces Management Changes

Alcon Inc. Launches Clareon Presbyopia Correcting IOLs in India

Dividend of CHF0.16 announced

Alcon Inc. Proposes Dividend for the Year 2023

Full year 2023 earnings: EPS exceeds analyst expectations

Alcon Announces Positive Topline Results from Phase 3 Comet Trials of AR-15512, A Novel Topical Drug Candidate for Dry Eye

Alcon Inc., Annual General Meeting, May 08, 2024

Alcon Inc. Revises Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations

Alcon Inc. Showcases Cloud-Based Planning and World-Class Digital Technologies During AAO 2023

Alcon Launches Total30 Multifocal Contact Lenses for Patients with Presbyopia

Alcon: Buy An Eyecare Leader With $2 Billion In Quarterly Sales

Alcon Inc. Raises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$0.34 (vs US$0.30 in 2Q 2022)

Alcon: Lackluster Growth Given Its Valuation

Alcon: The Steady Force Of 'Boring'

Price target increased by 8.4% to US$85.32

Price target increased by 7.9% to US$84.07

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alcon Inc. Provides Earnings Guidance for the Year 2023

Alcon Announces Results from a New Study Presented at the American Society of Cataract and Refractive Surgery Annual Meeting

Alcon Inc. Approves Dividend

Upcoming dividend of CHF0.14 per share at 0.3% yield

Full year 2022 earnings: EPS misses analyst expectations

Alcon Inc. Announces Settlement of Litigation Related to Femtosecond Laser Assisted Cataract Surgery Devices

Alcon reached $199M settlement with J&J Surgical Vision

Alcon Launches New Total Toric Lenses for Astigmatic Patients

Alcon: Case Of Growth Destructive To Value, Reiterate Hold At 24x Earnings

Alcon Inc., Annual General Meeting, May 05, 2023

Alcon Introduces a Premium, Reusable Toric Lens with Launch of TOTAL30 for Astigmatism

Alcon a buy at Mizuho on 'eyecare dominance'

Alcon Inc. Updates Earnings Guidance for the Year 2022

Third quarter 2022 earnings: EPS exceeds analyst expectations

Insufficient new directors

Alcon Inc. Revises Revenue Guidance for 2022

Alcon Q3 2022 Earnings Preview

Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022

Alcon: Looking To Break Downtrend Before Entry

Alcon Inc. (SWX:ALC) entered into a definitive merger agreement to acquire Aerie Pharmaceuticals, Inc. (NasdaqGM:AERI) for approximately $770 million.

Alcon downgraded to hold at Societe Generale on macro headwinds

Second quarter 2022 earnings: EPS exceeds analyst expectations

Alcon Inc. Revises Revenue Guidance for 2022

Alcon: Revisiting The Investment Thesis

Alcon Inc. (SWX:ALC) acquired EYSUVIS® from Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $60 million.

Alcon Inc. Reaffirms Earnings Guidance for the Fiscal 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Alcon Inc. Declares Dividend for 2021

Insufficient new directors

Alcon Announces Key Data to Be Presented at This Year’s American Society of Cataract and Refractive Surgery Meeting on its SMART Solutions for Cataract Surgery

Upcoming dividend of CHF0.13 per share

The Recent Pullback Makes Alcon More Attractive

Alcon Inc. Announces Launch of Clareon Portfolio in the U.S

Full year 2021 earnings: EPS exceeds analyst expectations

Alcon Inc. Proposes Dividend

Alcon Inc. Announces Launch of Systane Complete Preservative-Free Lubricant Eye Drops in Europe

Alcon: Good Quarterly Results, But It Is Still Expensive

Alcon Continues Its Successful Rollout of Precision1 Daily Disposable Contact Lenses, Now Available in Key Markets Throughout Latin America, Asia & Europe

Third quarter 2021 earnings released: EPS US$0.004 (vs US$0.30 loss in 3Q 2020)